Skip to main content
Premium Trial:

Request an Annual Quote

Jim Mullen

Jim Mullen has been elected to the board of directors of Thermo Fisher Scientific, bringing the total number of board members to 12. Previously, he was the CEO of Patheon, which Thermo Fisher acquired last year. Prior to that, he was the president and CEO of Biogen Idec. Mullen holds a bachelor of science degree in chemical engineering from Rensselaer Polytechnic Institute and a master's degree in business from Villanova University.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.